Methods of treating or preventing stent thrombosis

Abstract

The present invention is directed to the following: methods of treating or preventing stent thrombosis using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; methods of reducing mortality in a subject undergoing stent implantation using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; medicaments comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation; pharmaceutical compositions comprising cangrelor and bivalirudin; and methods of preparing a medicament comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation.

What is claimed is: 
     
         1 . A method of treating or preventing stent thrombosis in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition comprising cangrelor, thereby treating or preventing stent thrombosis in a subject. 
     
     
         2 . The method of  claim 1 , wherein the pharmaceutical composition further comprises bivalirudin. 
     
     
         3 . A method of reducing mortality in a subject undergoing stent implantation, comprising administering to the subject an effective amount of a pharmaceutical composition comprising cangrelor, thereby reducing mortality in a subject undergoing stent implantation. 
     
     
         4 . The method of  claim 3 , wherein the pharmaceutical composition further comprises bivalirudin. 
     
     
         5 . A method of treating or preventing myocardial infarction in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition comprising cangrelor, thereby treating or preventing myocardial infarction in a subject. 
     
     
         6 . The method of  claim 5 , wherein the pharmaceutical composition further comprises bivalirudin. 
     
     
         7 . The method of  claim 1 , wherein stent thrombosis is induced by implantation of a bare-metal stent or a drug-eluting stent into the subject. 
     
     
         8 . The method of  claim 1 , wherein stent thrombosis is intraprocedural stent thrombosis, acute stent thrombosis, sub-acute stent thrombosis, late stent thrombosis or very late stent thrombosis. 
     
     
         9 . The method of  claim 1 , wherein preventing stent thrombosis is prevention during percutaneous coronary intervention (PCI) or other vascular stent implantation. 
     
     
         10 . The method of  claim 3 , wherein stent implantation is implantation of a bare-metal stent or a drug-eluting stent into the subject. 
     
     
         11 . The method of  claim 3 , wherein stent implantation is during percutaneous coronary intervention (PCI) or other vascular stent implantation. 
     
     
         12 . The method of  claim 5 , wherein myocardial infarction is induced by implantation of a bare-metal stent or a drug-eluting stent into the subject. 
     
     
         13 . The method of  claim 5 , wherein myocardial infarction is caused by intraprocedural stent thrombosis, acute stent thrombosis, sub-acute stent thrombosis, late stent thrombosis, very late stent thrombosis, or occlusion of a coronary artery. 
     
     
         14 . The method of  claim 5 , wherein myocardial infarction is experienced during percutaneous coronary intervention (PCI) or other vascular stent implantation. 
     
     
         15 . The method of  claim 1 ,  3 , or  5 , wherein the subject is undergoing vascular stent implantation. 
     
     
         16 . The method of  claim 1 ,  3 , or  5 , wherein the subject has undergone vascular stent implantation. 
     
     
         17 . The method of  claim 1 ,  3 , or  5 , wherein the pharmaceutical composition is administered to the subject orally, as an intravenous bolus, as a continuous intravenous infusion, or as an intravenous bolus followed by a continuous intravenous infusion. 
     
     
         18 . The method of  claim 17 , wherein the pharmaceutical composition is administered to the subject in as a continuous intravenous infusion over a period of at least about two hours. 
     
     
         19 . The method of  claim 1  or  3 , wherein the pharmaceutical composition is administered to the subject orally, as an intravenous bolus, as a continuous intravenous infusion, or as an intravenous bolus followed by a continuous intravenous infusion within about 1 hour prior to beginning stent implantation. 
     
     
         20 . The method of  claim 1  or  3 , wherein the pharmaceutical composition is administered to the subject orally, as an intravenous bolus, as a continuous intravenous infusion, or as an intravenous bolus followed by a continuous intravenous infusion during stent implantation. 
     
     
         21 . The method of  claim 1  or  3 , wherein the pharmaceutical composition is administered to the subject orally, as an intravenous bolus, as a continuous intravenous infusion, or as an intravenous bolus followed by a continuous intravenous infusion after completion of stent implantation. 
     
     
         22 . The method of  claim 1  or  3 , wherein the pharmaceutical composition is administered to the subject orally, as an intravenous bolus, as a continuous intravenous infusion, or as an intravenous bolus followed by a continuous intravenous infusion about 1 hour prior to stent implantation; and administered to the subject orally, as an intravenous bolus, as a continuous intravenous infusion, or as an intravenous bolus followed by a continuous intravenous infusion during the period of stent implantation. 
     
     
         23 . The method of  claim 1  or  3 , wherein the pharmaceutical composition is administered to the subject orally, as an intravenous bolus, as a continuous intravenous infusion, or as an intravenous bolus followed by a continuous intravenous infusion about 1 hour prior to stent implantation; administered to the subject orally, as an intravenous bolus, as a continuous intravenous infusion, or as an intravenous bolus followed by a continuous intravenous infusion during the period of stent implantation; and administered to the subject orally, as an intravenous bolus, as a continuous intravenous infusion, or as an intravenous bolus followed by a continuous intravenous infusion for a period of about 2 hours upon completion of implantation. 
     
     
         24 . The method of  claim 1  or  3 , wherein the pharmaceutical composition is administered to the subject orally, as an intravenous bolus, as a continuous intravenous infusion, or as an intravenous bolus followed by a continuous intravenous infusion during the period of stent implantation; and administered to the subject orally, as an intravenous bolus, as a continuous intravenous infusion, or as an intravenous bolus followed by a continuous intravenous infusion for a period of about 2 hours upon completion of implantation. 
     
     
         25 . The methods of  claim 3  or  4 , wherein mortality is reduced over a period of about one year after stent implantation. 
     
     
         26 . The method of  claim 1 ,  3 , or  5 , wherein the pharmaceutical composition comprises about 1 mg/mL cangrelor. 
     
     
         27 . The method of  claim 1 ,  3 , or  5 , wherein the pharmaceutical composition comprises about 5 mg/mL cangrelor. 
     
     
         28 . The method of  claim 2 ,  4 , or  6 , wherein the pharmaceutical composition comprises about 1 mg/mL cangrelor and about 1 mg/mL bivalirudin. 
     
     
         29 . The method of  claim 2 ,  4 , or  6 , wherein the pharmaceutical composition comprises about 1 mg/mL cangrelor and about 5 mg/mL bivalirudin. 
     
     
         30 . The method of  claim 2 ,  4 , or  6 , wherein the pharmaceutical composition comprises about 5 mg/mL cangrelor and about 1 mg/mL bivalirudin. 
     
     
         31 . The method of  claim 2 ,  4 , or  6 , wherein the pharmaceutical composition comprises about 5 mg/mL cangrelor and about 5 mg/mL bivalirudin.